AVY — Avery Dennison Corporation

The tape and the fundamentals are telling different stories as of 2026-09-13. The July 30, 2026 print was genuinely strong: net sales +10.9% YoY to $2.46B (7.6% organic), adjusted EPS +19.4% to $2.89, a ~17% consensus beat, a 4.6% single-day jump, and a raised full-year adjusted EPS guide of $10.00-$10.30. Sell-side is constructive (13 Buys, 5 Holds, 0 Sells; average target $200.25). But the stock has since given it all back: -3.24% over one week, -6.44% over one month, only +6.36% over three months, and it sits below its 20-, 50- and 200-day moving averages. The market is looking through the H1 beat — which was flattered by roughly $0.25/share of European and Asian customer pre-buying — and pricing the roughly $0.50/share sequential Q3 destocking step-down instead. That's a 'show me' posture, not a bull or bear one.

Revenue growth has clearly inflected upward, not decelerated. Year-over-year revenue growth ran +1.5% (Q3 2025), +3.9% (Q4 2025), +7.0% (Q1 2026), +10.9% (Q2 2026) — four straight quarters of acceleration off a genuinely flat 2023-2025 base where quarterly revenue sat in a narrow $2.10B-$2.27B band. Gross margin is stable-to-better: 28.66% in Q3 2025 to 29.62% in Q2 2026, the highest of the last twelve quarters. GAAP operating margin has been range-bound between 11.83% and 12.92% for three years with no structural expansion — Q2 2026 GAAP operating margin of 12.73% was actually ~18bp below Q2 2025 despite the revenue surge, because the quarter absorbed restructuring charges (roughly 600 roles eliminated in 2026). Adjusting for the ~$0.22/share GAAP-to-adjusted gap, operating margin expanded to roughly 13.6% from 12.9%. EPS progression is arithmetic and steady: $2.13, $2.15, $2.18, then $2.67 GAAP / $2.89 adjusted in Q2 2026. The clearest structural change is cash: TTM free cash flow through Q2 2026 is $1.06B versus $635M in the comparable prior-year period, with Q2 2026 alone producing a record $369M — though part of that is a temporarily light capex run rate ($170.5M TTM, versus $267M in 2023). Important nuance: the Q2 revenue surge is partly customer pre-buying that reverses in Q3, so expect a sequential EPS step down, not a trend break. The underlying growth — mid-to-high single digit organics plus RFID — is real.

Cheap versus its own history, roughly fair versus peers. As of 2026-09-13 the stock trades at 18.55x TTM EPS of $9.19 and about 16.6x the $10.186 next-FY consensus EPS, against a 5-year average TTM P/E of 23.69x. Price/sales is 1.40x versus a 5-year average of 1.81x — a discount on both. The cash-flow math is the strongest argument: $1.06B TTM FCF on a $12.96B market cap is an 8.2% free cash flow yield, backing a 2.2% dividend yield that has now been paid and raised for 56 consecutive years. ROE is 30.7%, ROIC 12.3%, EV/EBITDA 12.06x. Two caveats keep this from being a screaming bargain: (1) the 23.69x 5-year average was set in a lower-rate regime, so some of the 'discount' is regime change rather than mispricing; (2) general packaging peers (Amcor, Ball) trade at comparable or lower EV/EBITDA, so AVY isn't cheap on a relative basis — it's cheap against itself. Ignore the 9.78 PEG ratio entirely; it is an artifact of a depressed trailing growth denominator and is not informative.

The key tell as of 2026-09-13 is that the stock has given back the entire post-earnings move despite a raised guide. That means the market is not extrapolating Q2's +19.4% adjusted EPS growth — it is pricing something close to the $10.00-$10.30 FY2026 adjusted range as the ceiling, and treating the H1 pre-buy as borrowed rather than earned. This is a reasonable, conservative read. The setup therefore turns on Q3: if management absorbs the ~$0.50/share destocking hit and still lands inside the full-year range, then 2027 consensus of $10.186 (which implies almost no growth off the FY2026 guide midpoint of $10.15) is too low, and the stock is mispriced. If Q3 shows the destocking is bigger, longer, or spreading beyond Europe/Asia into North American retail, then even 16.6x forward is not a floor and the low end of the 52-week range comes back into play. Watch the guidance language on Q3, not the Q3 print itself.

Weak but not washed out, as of 2026-09-13. RSI(14) was 41.5 — below neutral, well above oversold. The stock sits 4.12% below its 20-day SMA (implied ~$176.66), 0.69% below its 50-day (~$170.56), and 2.16% below its 200-day (~$173.12). That combination — furthest below the shortest moving average, closest to the longest — describes a stock drifting down off a failed rally rather than a trending breakdown. The three-month return is still +6.36% against a -6.44% one-month return, so this is range-bound behavior inside a wide $152-$200 band, currently in the lower-middle. Entry-timing implication: there is no technical urgency to buy here. A reclaim of the 200-day near $173 would be the first genuine stabilization signal; a flush toward $152-$158 with RSI in the low 30s would be the higher-conviction entry. Given the Q3 report lands in late October, expect soft technicals to persist until then.

• Rate expectations and the discount rate: AVY is an ~18-19x earnings, 2.2%-yielding industrial, so the 10-year yield and Fed path move the multiple more than near-term EPS. The 5-year average P/E of 23.69x was built in a lower-rate era — that gap is partly regime, not opportunity.
• Retail and apparel inventory cycles: RFID and label volumes track apparel sell-through and retail restocking. H1 2026 flipped from customer pre-buying (roughly $0.25/share benefit in Q2) to destocking from July, guided as a roughly $0.50/share sequential Q3 hit.
• Packaging sector rotation: capital has favored lower-multiple, higher-yield names (Amcor, Smurfit Westrock) over premium-multiple compounders. AVY sits awkwardly between the two buckets and can get de-rated with the group regardless of its own results.
• Input costs and logistics: resin, paper and adhesive raw materials plus freight and energy drive the price-cost spread, which management expects to normalize to roughly neutral by Q3 2026 after sequential compression earlier in the year.
• Trade policy, tariffs and FX: Europe and Asia are material markets and were the source of the H1 pre-buy, meaning tariff-driven pull-forward and dollar strength add quarter-to-quarter noise to reported growth that doesn't reflect underlying demand.

• Q3 2026 earnings (late October 2026): the single most important datapoint. Investors need to see whether the guided ~$0.50/share sequential destocking hit lands and whether organic volume plus RFID growth offsets it enough to hold the full-year $10.00-$10.30 adjusted EPS range.
• Cost-savings realization from the 2026 restructuring (~600 roles eliminated): structural margin leverage that should flow into 2027 numbers and could reset the earnings base higher than consensus assumes.
• RFID / digital identification growth: management projects 3-5% H2 2026 growth in this highest-value secular segment. Share gains or expansion into new verticals beyond apparel would justify a premium multiple.
• Capital returns: 56 consecutive years of dividend increases (2.2% yield) plus ongoing buybacks — an acceleration of repurchases at 16.6x forward earnings would be a strong signal.
• Multiple re-rating if rates fall or if management guides 2027 to double-digit EPS growth at the Q4 print, given the stock trades ~5 multiple points below its own 5-year average.

• Destocking proves larger or longer than the guided ~$0.50/share Q3 headwind and bleeds into Q4 2026 and 2027. H1 2026 revenue was flattered by pre-buying, so the true organic run-rate is less obvious than the headline 10.9% growth implies.
• Leverage with a thin equity cushion: total debt of roughly $3.7B against just $2.32B of stockholders' equity (D/E 1.58), only $227M of cash, a 1.13 current ratio and a 0.79 quick ratio. Not distressed given $1.06B of TTM FCF, but there is little slack if volumes roll over.
• Multiple compression: if rates stay higher for longer, a high-teens forward multiple may simply be the correct clearing level for this business, capping upside regardless of execution.
• Cyclical end-markets: apparel/retail, logistics and industrial labels are economically sensitive, and a consumer slowdown hits volume and mix simultaneously with the price-cost spread.
• Base label materials is a competitive, semi-commoditized market (UPM Raflatac, CCL, Lintec); in a soft volume environment, pricing discipline can erode quickly and take the 29% gross margin with it.

AVY is a genuinely good business — 12.3% ROIC, 30.7% ROE, $1.06B of TTM free cash flow on a $12.96B market cap, 56 straight years of dividend increases, and a real secular kicker in RFID — available at 16.6x forward earnings versus its own 23.69x five-year average. The Q3 destocking headwind is well telegraphed and is a pull-forward reversal rather than demand destruction, which is why I read the recent ~6% one-month pullback as an accumulation opportunity rather than a warning. That said, it is not a compelling buy at $169 with RSI at 41.5, price below all three major moving averages, and the Q3 print still unproven — the better entries are either below $160 or after October confirms the destocking was a one-quarter event.

Blended forward-multiple and EV/EBITDA approach, calculated as of 2026-09-13. Applied 19x to the $10.186 next-FY consensus EPS, giving $193.5 — a multiple justified as sitting between the current 16.6x forward and the 5-year average of 23.69x, reflecting high-single-digit EPS growth, 12.3% ROIC and a 2.2% dividend yield in a higher-rate regime than the 5-year average was set in. Cross-checked with 13.0x TTM EBITDA of ~$1.36B = ~$17.7B EV, less ~$3.45B net debt = ~$14.23B equity, or $186.0 per share on ~76.5M shares. Blending the two (roughly $193.5 and $186.0) yields about $190, which implies 18.65x forward EPS and a 7.3% free cash flow yield — deliberately below the $200.25 sell-side consensus average.